Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer

Medicine and Dentistry

• Durvalumab 100%
• Progression Free Survival 54%
• Radiation Therapy 36%
• Adverse Event 27%
• Disease Exacerbation 27%
• Survival Rate 27%
• Lung Cancer 27%
• Distant Metastasis 18%
• Stage 3 18%
• Body Weight 9%
• Antibody 9%
• Ligand 9%
• Overall Survival 9%
• Platinum 9%
• Hazard Ratio 9%
• Pneumonia 9%
• Interim Analysis 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Durvalumab 100%
• Progression Free Survival 54%
• Adverse Event 27%
• Disease Exacerbation 27%
• Lung Cancer 27%
• Survival Rate 27%
• Distant Metastasis 18%
• Ligand 9%
• Antibody 9%
• Platinum 9%
• Overall Survival 9%
• Pneumonia 9%

Agricultural and Biological Sciences

• Survival Rate 100%
• Confidence Interval 100%
• Body Weight 33%
• Antibodies 33%